Company intelligence / Profile preview

Chain Bridge I

Dover, Delaware, United States

Ownership: Private
Development stage: Other

Overview

Chain Bridge I is a blank-check/special purpose acquisition company (SPAC) whose sole business is to identify and effect a merger, acquisition, or similar business combination with one or more businesses. As of July 2024, it is merging with Phytanix Bio, a life sciences company focused on cannabinoid and cannabinoid-like medicines. The combined company will be named Phytanix Inc.

Industry: Investors

Beyond the preview

Go deeper on Chain Bridge I.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chain Bridge I.

Explore the full profile